Overview

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Status:
Completed
Trial end date:
2008-03-10
Target enrollment:
Participant gender:
Summary
This study will use single escalating doses of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and in subjects with Type 2 Diabetes Mellitus.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline